Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

Rhea-AI Summary

MannKind Corporation announces a manufacturing milestone and hosts Connecticut Governor for a tour of its headquarters. The company has successfully scaled-up operations for increased production capacity of Tyvaso DPI® through its partnership with United Therapeutics. Construction is ongoing for new manufacturing space to expand production. MannKind has experienced over a 250% increase in its Connecticut workforce in the past two years.

Positive

• MannKind successfully scaled-up operations for increased production capacity of Tyvaso DPI®
• $60 million investment in expansion project
• Construction underway for new manufacturing space to expand production
• Over 250% increase in Connecticut workforce in the past two years

Negative

• None.

DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI^®.

Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.

DATE/TIMES:	MONDAY, JUNE 12, 2023
	10:00 a.m. – 11:00 a.m.
LOCATION:	MannKind
	40 Taylor Street (Danbury, CT)
VISUALS/SOUND:	- Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella
	- Construction underway on “clean rooms” and spray dry equipment in new manufacturing space
	- Demonstration of MannKind’s innovative Technosphere® particle and device technologies
	- Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI
MANNKIND:	MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

CONTACT:	MannKind Corporate Communications
	Christie Iacangelo (on-site)
	(818) 292-3500 (mobile)
	ciacangelo@mnkd.com

FAQ

What is the manufacturing milestone that MannKind has reached?

MannKind has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.

Who is MannKind partnering with for the expansion project?

MannKind is partnering with United Therapeutics for the expansion project.

How much is the investment for the expansion project?

The expansion project represents a $60 million investment.

What is MannKind currently constructing?

MannKind is currently constructing new manufacturing space to expand production.

How much has MannKind's Connecticut workforce increased in the past two years?

MannKind has experienced over a 250% increase in its Connecticut workforce in the past two years.